Hemostemix Inc. (CVE:HEM – Get Free Report)’s share price reached a new 52-week low during mid-day trading on Monday . The company traded as low as C$0.05 and last traded at C$0.05, with a volume of 112196 shares trading hands. The stock had previously closed at C$0.06.
Hemostemix Trading Down 9.1%
The company has a debt-to-equity ratio of -72.45, a quick ratio of 0.48 and a current ratio of 0.49. The company has a market capitalization of C$9.89 million, a price-to-earnings ratio of -1.72 and a beta of 0.59. The business’s 50-day simple moving average is C$0.07 and its 200-day simple moving average is C$0.08.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery.
Recommended Stories
- Five stocks we like better than Hemostemix
- SpaceX Gets the Attention, But These 4 Stocks Could Get the Returns
- Microsoft Stock Discount May Be Ending as AI Catalysts Build
- Apparel Earnings Winners and Losers: Ralph Lauren Takes Off
- Why Walmart, Target and TJX Got Such Different Reactions After Earnings
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
